Enanta Doses First Patient in Zelicapavir Phase 2b/3 RSV Trial
Enanta Pharmaceuticals says the first patient has been dosed in RESOLVE, its global Phase 2b/3 trial of zelicapavir for RSV.
Story updates
11:09:09 AM UTC
SquawkNews
Enanta began dosing in RESOLVE, a global Phase 2b/3 trial of zelicapavir in high-risk adults with RSV. The Phase 2b portion will enroll at least 200 patients, with topline data expected in 2027; the Phase 3 plans to enroll ~660 patients.Material DetailsContext by AI AnalystThis is a mid-stage devel…